ACT, Korean Biotech Form New Stem Cell Joint Venture
By Mass High Tech,
Mass High Tech
| 12. 02. 2008
Worcester biotech Advanced Cell Technology Inc. and Korean biotech CHA Biotech Co. Ltd. have formed a new stem cell technology development company called Allied Cell Technology, to be based in Worcester. The international joint venture will use ACT’s hemangioblast cell technology to develop human blood cells.
The developments may be used to address the human blood shortage, particularly in military situations.
Allied Cell Technology will be majority owned by CHA, with ACT (OTC: ACTC) licensing its technology for a $500,000 license fee from CHA, the companies reported. ACT will also work to pull in funding grants for the new joint venture.
Leading the new company in Worcester will be Young Chung, as well as Shi-Jiang Lu and the ACT hemangioblast team. Robert Lanza of ACT will serve as the chief scientific advisor of Allied Cell Technology.
ACT is operating on a limited budget, but has reduced its debt from $49 million to $13 million in the last three years, according to CEO William M. Caldwell IV. To cut operating expenses, the company announced its plans to close a Charlestown research...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...
